[Form 4] Gilead Sciences Inc Insider Trading Activity

Rhea-AI Filing Summary

Johanna Mercier, Chief Commercial Officer of Gilead Sciences (GILD), reported multiple transactions on 08/15/2025 executed under a Rule 10b5-1 trading plan adopted Feb 20, 2025. The filing shows a series of option-related acquisitions and open-market sales in common stock: total reported sales on that date equal 28,000 shares at prices ranging roughly from $117.91 to $119.01, and multiple option exercises/acquisitions at an exercise price of $66.64. Following the reported transactions, the filing lists beneficial ownership levels of common stock as low as 114,168 shares and various counts of options/derivatives remaining outstanding. The Form 4 also discloses that the related options have a four-year vesting schedule with 25% vesting after one year and the remainder vesting quarterly thereafter.

Positive

• Transactions executed under a Rule 10b5-1 trading plan, indicating pre-established compliance documentation
• Vesting schedule disclosed for the non-qualified stock options (four-year schedule; 25% at first anniversary, remainder quarterly)

Negative

• Insider sold 28,000 shares on 08/15/2025 at prices roughly between $117.91 and $119.01, reducing reported beneficial ownership to as low as 114,168 shares

Insights

Financial Analyst

TL;DR: Insider executed option acquisitions and sold 28,000 shares under a 10b5-1 plan; transactions appear routine and disclosed.

The Form 4 reports coordinated exercises/acquisitions of non-qualified stock options at a $66.64 strike and contemporaneous open-market sales executed under a Rule 10b5-1 plan adopted Feb 20, 2025. Aggregate sales reported on 08/15/2025 total 28,000 shares at prices in the ~$117.91–$119.01 range, which generated material cash proceeds relative to a single-person insider but are not, by themselves, a company-level event. The filing also documents remaining equity and option holdings (common shares and options shown at various post-transaction balances, e.g., 114,168 shares beneficially owned). For investors, these are governance/compliance disclosures rather than operating or financial performance signals.

Corporate Governance Expert

TL;DR: Transactions executed under a documented 10b5-1 plan with full vesting schedule disclosure — consistent with standard insider liquidity practices.

The Form 4 clearly states the trades were made pursuant to a Rule 10b5-1 trading plan, which provides an affirmative defense to insider trading allegations when properly adopted and followed. The filing includes the vesting schedule for the options (four-year schedule, 25% at year one, remainder quarterly at 6.25%), and provides ranges for sale prices with an offer to supply detailed trade-by-trade pricing on request. Documentation and disclosure appear complete for regulatory compliance; no additional governance issues are identified within the filing itself.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mercier Johanna

(Last) (First) (Middle)

GILEAD SCIENCES, INC.

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2025		M(1)		11,800	A	$66.64	128,968	D
Common Stock	08/15/2025		S(1)		11,800	D	$118.5044(2)	117,168	D
Common Stock	08/15/2025		M(1)		700	A	$66.64	117,868	D
Common Stock	08/15/2025		S(1)		700	D	$118.9686(3)	117,168	D
Common Stock	08/15/2025		M(1)		11,800	A	$66.64	128,968	D
Common Stock	08/15/2025		S(1)		11,800	D	$118.5089(2)	117,168	D
Common Stock	08/15/2025		M(1)		700	A	$66.64	117,868	D
Common Stock	08/15/2025		S(1)		700	D	$118.9686(3)	117,168	D
Common Stock	08/15/2025		S(1)		2,800	D	$118.5074(4)	114,368	D
Common Stock	08/15/2025		S(1)		200	D	$118.965(5)	114,168	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-qualified Stock Option (Right to Buy)	$66.64	08/15/2025		M(1)			11,800	(6)	07/24/2029	Common Stock	11,800	$0	111,310	D
Non-qualified Stock Option (Right to Buy)	$66.64	08/15/2025		M(1)			700	(6)	07/24/2029	Common Stock	700	$0	110,610	D
Non-qualified Stock Option (Right to Buy)	$66.64	08/15/2025		M(1)			11,800	(6)	07/24/2029	Common Stock	11,800	$0	98,810	D
Non-qualified Stock Option (Right to Buy)	$66.64	08/15/2025		M(1)			700	(6)	07/24/2029	Common Stock	700	$0	98,110	D

Explanation of Responses:

1. The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

2. Sales prices for the transactions reported here range from $117.91 to $118.89. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

3. Sales prices for the transactions reported here range from $118.91 to $119.01. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or the shareowners upon request.

4. Sales prices for the transactions reported here range from $117.91 to $118.85. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

5. Sales prices for the transactions reported here range from $118.95 to $118.98. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

6. The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Remarks:

	/s/ Edward S. Son by Power of Attorney for Johanna Mercier	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Johanna Mercier (GILD) report on Form 4 for 08/15/2025?

The Form 4 shows option acquisitions/exercises at a $66.64 strike and open-market sales executed under a Rule 10b5-1 plan, with total reported sales of 28,000 shares on 08/15/2025.

Were the transactions made under a 10b5-1 plan for GILD insider trades?

Yes. The filing states the trades were made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

At what prices were the GILD shares sold by the reporting person?

The Form 4 reports sale price ranges roughly from $117.91 to $119.01; the filer offers to provide detailed per-trade pricing on request.

How many shares did the reporting person own after the reported transactions?

Following the reported transactions, the filing lists beneficial ownership as low as 114,168 shares of common stock (direct ownership).

What is the vesting schedule for the reported options in the Form 4?

The options have a four-year vesting schedule: 25% vest on the first anniversary of grant, with the balance vesting quarterly at 6.25% thereafter.